Skip to main content
Log in

Ciprofloxacin nanocrystals and N-acetylcysteine co-solidified powders for pulmonary drug delivery: development and in vitro and in vivo characterization

  • Research paper
  • Published:
Journal of Nanoparticle Research Aims and scope Submit manuscript

Abstract

This study evaluated the feasibility of ciprofloxacin nanocrystals dry powder inhalations (DPIs) co-delivered with N-acetylcysteine (NAC) to improve the drug permeability and pulmonary bioavailability. The NAC could be reducing the viscosity of the sputum and causing it to liquefy, by breaks DNA fibers in sputum and purulent sputum. The ciprofloxacin nanocrystals, stabilized by 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine grafted N-[methoxy (polyethylene glycols)-2000] (DSPE-mPEG2000), was prepared by anti-solvent precipitation technology. The powder contained ciprofloxacin nanocrystals and N-acetyl-cysteine was obtained as a result of freeze-drying and spray-drying, respectively. The powder was coupled with inhaled lactose and the DPI of ciprofloxacin nanocrystals/NAC co-delivery system was obtained. The in vitro characteristics, including particle size and distribution, morphology, crystalline state, stability, flowability, aerosol performance, and in vivo image were evaluated. The spray-dried DPI of ciprofloxacin nanocrystals/NAC co-delivery system exhibited stratified in vitro and in vivo aerosol performance. This study demonstrated that spray-dried DPI system with a synergistic effect and meanwhile a better flowability is desirable for enhanced pulmonary drug delivery without severe lung injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Abbreviations

DPIs:

Dry powder inhalations

DPI:

Dry powder inhaler

NAC:

N-acetyl-cysteine

DSPE-mPEG2000:

1,2-Distearoyl-sn-glycero-3-phosphoethanolamine grafted N-[methoxy (polyethylene glycols)-2000]

MIC:

Minimum inhibitory concentration

MDI:

Metered-dose inhaler

CPFX:

Ciprofloxacin

NCFB:

Non-cystic fibrosis bronchiectasis

mPEG2000:

Methoxy-polyethylene glycols-2000

DSPE:

1,2-Distearoyl-sn-glycero-3-phosphoethanolamine

PVP K-30:

Polyvinylpyrrolidone K-30

CDI:

N,N′-Carbonyldiimidazole

DMAP:

4-Dimethylaminopyridine

DiR:

1,1-Dioctadecyl-3,3,3,3-tetramethylindotricarbocyaine iodide

FTIR:

Fourier transform infrared spectroscopy

1H NMR:

1H-nuclear magnetic resonance

DLS:

Dynamic light scattering

PDI:

Polydispersity index

TEM:

Transmission electron microscope

CI:

Carr’s index

SEM:

Scanning electron microscope

XRPD:

X-ray powder diffractometer

DSC:

Differential scanning calorimetry

TGA:

Thermogravimetric analysis

TSI:

Twin stage impinger

ED:

Emitted dose

RD:

Recovered dose

FPF:

Fine particle fraction

References

Download references

Funding

This work was supported by the Shandong Provincial Natural Science Foundation (ZR2019MH105), the projects of “20 Colleges and Universities” in Jinan (2019GXRC068).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yancai Wang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guan, W., Liu, Y., Ding, S. et al. Ciprofloxacin nanocrystals and N-acetylcysteine co-solidified powders for pulmonary drug delivery: development and in vitro and in vivo characterization. J Nanopart Res 24, 41 (2022). https://doi.org/10.1007/s11051-022-05427-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11051-022-05427-1

Keywords

Navigation